RT Journal Article
T1 The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.
A1 Macias, Rocio I R
A1 Banales, Jesus M
A1 Sangro, Bruno
A1 Muntané, Jordi
A1 Avila, Matias A
A1 Lozano, Elisa
A1 Perugorria, Maria J
A1 Padillo, Francisco J
A1 Bujanda, Luis
A1 Marin, Jose J G
K1 Biliary cancer
K1 Biomarker
K1 Differential diagnosis
K1 Liver cancer
K1 Omics
AB The poor prognosis of cholangiocarcinoma (CCA) is in part due to late diagnosis, which is currently achieved by a combination of clinical, radiological and histological approaches. Available biomarkers determined in serum and biopsy samples to assist in CCA diagnosis are not sufficiently sensitive and specific. Therefore, the identification of new biomarkers, preferably those obtained by minimally invasive methods, such as liquid biopsy, is important. The development of innovative technologies has permitted to identify a significant number of genetic, epigenetic, proteomic and metabolomic CCA features with potential clinical usefulness in early diagnosis, prognosis or prediction of treatment response. Potential new candidates must be rigorously evaluated prior to entering routine clinical application. Unfortunately, to date, no such biomarker has achieved validation for these purposes. This review is an up-to-date of currently used biomarkers and the candidates with promising characteristics that could be included in the clinical practice in the next future. This article is part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
SN 0925-4439
YR 2017
FD 2017-08-04
LK http://hdl.handle.net/10668/11480
UL http://hdl.handle.net/10668/11480
LA en
DS RISalud
RD Apr 7, 2025